Thalia Therapeutics PLC
0GO
Company Profile
Business description
Thalia Therapeutics PLC is a specialist pharmaceutical company engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company engaged in the development of a Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The Group operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Contact
2 Portman Street
LondonW1H 6DU
GBRT: +44 2046100714
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
stocks
Alphabet Earnings: AI Monetisation continues to grow as hardware sales boost results
We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,025.40 | 12.80 | 0.14% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,837.30 | 505.26 | -0.97% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,294.42 | 335.77 | 1.46% |
| NASDAQ | 25,365.28 | 819.44 | -3.13% |
| Nikkei 225 | 63,290.11 | 1,369.36 | -2.12% |
| NZX 50 Index | 13,797.00 | 86.83 | 0.63% |
| S&P 500 | 7,574.15 | 146.24 | -1.89% |
| S&P/ASX 200 | 8,908.10 | 16.30 | 0.18% |
| SSE Composite Index | 3,599.02 | 52.42 | -1.44% |